NO813433L - Vannopploeselige derivater av cefalexin og fremstilling derav - Google Patents
Vannopploeselige derivater av cefalexin og fremstilling deravInfo
- Publication number
- NO813433L NO813433L NO813433A NO813433A NO813433L NO 813433 L NO813433 L NO 813433L NO 813433 A NO813433 A NO 813433A NO 813433 A NO813433 A NO 813433A NO 813433 L NO813433 L NO 813433L
- Authority
- NO
- Norway
- Prior art keywords
- cephalexin
- solution
- cation
- amino acid
- basic amino
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 5
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 title claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 18
- 229940106164 cephalexin Drugs 0.000 claims description 15
- 150000001768 cations Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- -1 Methylol derivatives of cephalexin Chemical class 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- 150000001340 alkali metals Chemical group 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 125000001477 organic nitrogen group Chemical group 0.000 claims description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 239000008098 formaldehyde solution Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000012265 solid product Substances 0.000 claims description 2
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical class O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 6
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940047526 cephalexin monohydrate Drugs 0.000 description 1
- 125000001271 cephalosporin group Chemical group 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/22—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with radicals containing only hydrogen and carbon atoms, attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cephalosporin Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT25267/80A IT1195762B (it) | 1980-10-13 | 1980-10-13 | Derivati idrosolubili della cefalexina e procedimento per la loro produzione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO813433L true NO813433L (no) | 1982-04-14 |
Family
ID=11216176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO813433A NO813433L (no) | 1980-10-13 | 1981-10-12 | Vannopploeselige derivater av cefalexin og fremstilling derav |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4471115A (de) |
| EP (1) | EP0049928B1 (de) |
| JP (1) | JPS5767583A (de) |
| KR (1) | KR880000691B1 (de) |
| AR (1) | AR229035A1 (de) |
| AT (1) | ATE35813T1 (de) |
| AU (1) | AU548333B2 (de) |
| BE (1) | BE890718A (de) |
| CA (1) | CA1181741A (de) |
| DE (1) | DE3176811D1 (de) |
| DK (1) | DK451281A (de) |
| ES (1) | ES506213A0 (de) |
| FR (1) | FR2491927B1 (de) |
| IT (1) | IT1195762B (de) |
| NO (1) | NO813433L (de) |
| PT (1) | PT73807B (de) |
| YU (1) | YU246381A (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7104141B2 (ja) * | 2018-02-28 | 2022-07-20 | ブリッジ バイオセラピューティクス インコーポレイテッド | 脂質化ペプチドの水溶性塩、その製造方法および用途 |
| BR112020019347A2 (pt) * | 2018-03-29 | 2021-02-17 | S.I.S Shulov Innovative Science Ltd. | composições farmacêuticas para inibição de citocinas inflamatórias |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1265315A (de) * | 1968-04-05 | 1972-03-01 | Glaxo Lab Ltd | |
| BE786924A (fr) * | 1971-07-28 | 1973-01-29 | Squibb & Sons Inc | Antibiotiques, leur preparation et leurs utilisations therapeutiques |
| US3796709A (en) * | 1971-11-19 | 1974-03-12 | Squibb & Sons Inc | (alpha-cyanamino)acetamidocephalosporins |
| BE792229A (fr) * | 1971-12-03 | 1973-06-01 | Bristol Myers Co | Agents antibacteriens heterocycliques azotes et procede pour les preparer |
| US3880842A (en) * | 1972-05-30 | 1975-04-29 | Squibb & Sons Inc | Cephalosporin derivatives |
| US3988326A (en) * | 1974-02-22 | 1976-10-26 | Meiji Seika Kaisha, Ltd. | Process for N-acylation of 7 amino cephem compounds |
-
1980
- 1980-10-13 IT IT25267/80A patent/IT1195762B/it active
-
1981
- 1981-04-17 JP JP56057257A patent/JPS5767583A/ja active Pending
- 1981-10-06 AT AT81201107T patent/ATE35813T1/de not_active IP Right Cessation
- 1981-10-06 DE DE8181201107T patent/DE3176811D1/de not_active Expired
- 1981-10-06 EP EP81201107A patent/EP0049928B1/de not_active Expired
- 1981-10-12 PT PT73807A patent/PT73807B/pt unknown
- 1981-10-12 AU AU76247/81A patent/AU548333B2/en not_active Ceased
- 1981-10-12 DK DK451281A patent/DK451281A/da not_active Application Discontinuation
- 1981-10-12 NO NO813433A patent/NO813433L/no unknown
- 1981-10-12 FR FR8119156A patent/FR2491927B1/fr not_active Expired
- 1981-10-13 BE BE0/206233A patent/BE890718A/fr not_active IP Right Cessation
- 1981-10-13 ES ES506213A patent/ES506213A0/es active Granted
- 1981-10-13 YU YU02463/81A patent/YU246381A/xx unknown
- 1981-10-13 KR KR1019810003864A patent/KR880000691B1/ko not_active Expired
- 1981-10-13 CA CA000387814A patent/CA1181741A/en not_active Expired
- 1981-10-13 AR AR287074A patent/AR229035A1/es active
-
1982
- 1982-12-22 US US06/452,159 patent/US4471115A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5767583A (en) | 1982-04-24 |
| CA1181741A (en) | 1985-01-29 |
| KR830007681A (ko) | 1983-11-04 |
| EP0049928A3 (en) | 1983-04-06 |
| DE3176811D1 (en) | 1988-08-25 |
| AU7624781A (en) | 1982-04-22 |
| ATE35813T1 (de) | 1988-08-15 |
| KR880000691B1 (ko) | 1988-04-23 |
| AU548333B2 (en) | 1985-12-05 |
| BE890718A (fr) | 1982-02-01 |
| PT73807A (fr) | 1981-11-01 |
| IT8025267A0 (it) | 1980-10-13 |
| FR2491927B1 (fr) | 1985-07-12 |
| FR2491927A1 (fr) | 1982-04-16 |
| ES8206533A1 (es) | 1982-08-16 |
| DK451281A (da) | 1982-04-14 |
| PT73807B (fr) | 1983-01-17 |
| AR229035A1 (es) | 1983-05-31 |
| IT1195762B (it) | 1988-10-27 |
| US4471115A (en) | 1984-09-11 |
| EP0049928A2 (de) | 1982-04-21 |
| YU246381A (en) | 1983-10-31 |
| EP0049928B1 (de) | 1988-07-20 |
| ES506213A0 (es) | 1982-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4409233A (en) | Highly concentrated preparations of dopa compounds | |
| AU688792B2 (en) | Stabilized prostaglandin e1 | |
| KR20090052355A (ko) | 순도가 높은 페메트렉세드 이산 및 이의 제조 방법 | |
| US4673666A (en) | 2-amino-3-ethoxycarbonylamino-6-(p-fluoro-benzylamino)-pyridine gluconate and pharmaceutical preparations containing it | |
| US5595986A (en) | Stably storable and readily water soluble composition of cephalosporin for injections | |
| RU2531276C2 (ru) | Цефдинира кислая соль и способ ее получения | |
| NO813433L (no) | Vannopploeselige derivater av cefalexin og fremstilling derav | |
| CA1043261A (en) | Cephalosporin-type antibiotic composition | |
| JPS63208522A (ja) | 凍結乾燥または沈殿セファロスポリン双性イオンおよび塩結合体 | |
| NO165223B (no) | Fremgangsmaate for fremstilling av et stabilt antibakterielt lyofilisat. | |
| EP0012495B1 (de) | Pharmazeutische Zusammensetzung enthaltend ein wasserlösliches Salz von Amoxycillin und Polyvinylpyrrolidon, und eine Ampulle die eine Einheitsdosis dieser Zusammensetzung enthält | |
| DK542089A (da) | Opbevaringsstabilt lyofikseret mdm-praeparat og fremgangsmaade til fremstilling deraf | |
| JP2958567B2 (ja) | 非経口用凍結乾燥ｂｍｙ―２８１４２ジ塩酸塩 | |
| US4144328A (en) | N,N,N-Trimethyl derivatives of polyene amphoteric antibiotics, process of producing same and pharmaceutical composition | |
| CA1075230A (en) | Process for preparing solid sodium amoxycillin | |
| KR101435244B1 (ko) | 목시플록사신 수성 제형 및 이의 제조방법 | |
| EP0029668B1 (de) | Injizierbare pharmazeutische Zusammensetzung und Doppelbehälter für diese Zusammensetzung | |
| De Stevens et al. | The chemistry and pharmacology of hydrotrichlorothiazide | |
| US6060498A (en) | Composition containing antitumor agent | |
| WO2006106529A1 (en) | A co-spray dried composition of cefepime with base and process for preparation thereof | |
| SU1558915A1 (ru) | 2-(5 @ -Нитрофурил)-2,3-дигидро-5Н-1,3,4-тиадиазоло[2,3-в]-хиназолинон-5, про вл ющий противомикробную активность | |
| DE2645144C2 (de) | Cephalosporine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel | |
| CS226174B2 (en) | Method of increasing sensitivity of bacteria to antibiotics | |
| Elliott et al. | 20. Bacteriostasis in the amino-acid series. Part I. Derivatives of alanine | |
| JPWO1997030706A1 (ja) | 抗腫瘍剤含有組成物 |